The weekly litigation news digest is live. Subscribe now

IP Verse

Eli Lilly competitive analysis

Loading summary...

Latest oppositions filed by Eli Lilly

Explore patent oppositions filed by Eli Lilly against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2784084
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHAug 30, 2021
EP2784084
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHMar 16, 2020
EP3045182
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide And Methods Using SameLABRYS BIOLOGICSDec 7, 2018
EP2475388
Use Of Il-33 Antagonists To Treat Fibrotic DiseaseMERCK SHARP & DOHMEAug 8, 2018
EP2579902
Method For Production Of F-18 Labeled Amyloid Beta LigandsPIRAMAL IMAGINGApr 12, 2018
EP1976558
Use Of A Pcv2 Immunogenic Composition For Lessening Clinical Symptoms In PigsBOEHRINGER INGELHEIM ANIMAL HEALTH USADec 14, 2017

Latest patents of Eli Lilly opposed by its competitors

Explore Eli Lilly's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2247558
Jul 3, 2024Novel Imaging Agents For Detecting Neurological Dysfunction1
EP3668568
Jun 12, 2024Dosage Measurement Module On Injection Pen1
EP3432949
May 1, 2024Determination Of A Dose Set And Delivered In A Medication Delivery Device1
EP4017557
Feb 7, 2024Methods And Apparatus For Aspects Of A Dose Detection System1
EP3697476
Nov 15, 2023Accelerated Testing Method Of Silicone Drainage In Syringes1
EP3846810
Oct 18, 2023Chronic Nightly Dosing Of Lasmiditan For Migraine Prevention1
EP3630164
Aug 23, 2023Dulaglutide For The Treatment Of Chronic Kidney Disease1
EP3810201
Aug 2, 2023Gip/Glp1 Agonist Compositions7
EP3258919
Nov 9, 2022Nasal Powder Formulation For Treatment Of Hypoglycemia1
EP3226944
Aug 10, 2022Needle Shield Puller Cap Assembly1

Latest PTAB cases involving Eli Lilly

Discover the latest PTAB cases involving Eli Lilly, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 17, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Eli Lilly

IPR2025-01346Aug 4, 2025BPI LABSELI LILLYPending
IPR2025-01024May 22, 2025EMPOWER CLINIC SERVICESELI LILLYPending Director Review
IPR2022-00796Apr 11, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00738Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2022-00739Mar 23, 2022ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
PGR2019-00043Apr 2, 2019ELI LILLYGENENTECHTerminated
IPR2018-01711Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01712Oct 1, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01710Sep 28, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision
IPR2018-01422Aug 8, 2018ELI LILLYTEVA PHARMACEUTICALSFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Eli Lilly with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ELI LILLY4251715
APOTEX - 236 -
TEVA PHARMACEUTICALS20916 - 12
TEVA PHARMACEUTICALS USA - - 16 -